

REMARKS

The above changes in the claims merely place this national phase application in the same condition as it was during Chapter II of the international phase, with the multiple dependencies being removed.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE".

Respectfully submitted,

YOUNG & THOMPSON

By



Benoît Castel
Attorney for Applicants
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 521-2297

April 19, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

6) Compounds as claimed in ~~one of claims~~claim 1, ~~3 and 5~~, comprising at least one group selected from among the group comprising nucleoside derivatives, oligonucleotides, nucleic acids (RNA, DNA), amino acids, peptides, proteins, monosaccharides, oligosaccharides, polysaccharides, fatty acids, simple lipids, complex lipids, folic acid, tetrahydrofolic acid, phosphoric acids, inositol, vitamins, co-enzymes, flavonoids, aldehydes, halohydrins and epoxides.

7) Compounds as claimed in ~~claims 5 and 6~~, in which R₂ is moreover selected from among the group comprising nucleoside derivatives, oligonucleotides, nucleic acids (RNA, DNA), amino acids, peptides, proteins, monosaccharides, oligosaccharides, polysaccharides, fatty acids, simple lipids, complex lipids, folic acid, tetrahydrofolic acid, phosphoric acids, inositol, vitamins, co-enzymes, flavonoids, aldehydes, halohydrins, phosphoepoxides of the formula (I) and epoxides

9) Compounds as claimed in ~~one of claims 3 to 5, 7 or 8~~claim 3 for the use thereof as therapeutically active substances.

10) Compounds as claimed in ~~one of claims 1 to 9~~claim 1 for the use thereof as T_γ9δ2 lymphocyte activators.

11) Compounds as claimed in ~~one of claims 1 to 10~~claim 1 for the use thereof as T_γ9δ2 lymphocyte antigens in a therapeutic composition, in particular an immunostimulant therapeutic composition or a vaccine, for primates.

14) Process as claimed in ~~one of claims 12 and 13~~,claim 12, wherein

the intermediate compound is reacted in a basic aqueous medium in order to convert the halohydrin functions of the intermediate compound into epoxide functions.

15) Composition for extracorporeal diagnostics, wherein it comprises at least one compound as claimed in ~~one of claims 3 to 5, 7 or 8:claim 3.~~

16) Therapeutic composition, wherein it comprises at least one compound as claimed in ~~one of claims 1 to 8:claim 1.~~

17) A therapeutic composition, wherein it comprises a quantity capable of being administered to a primate, in particular in contact with the peripheral bloodstream or topically, of at least one compound as claimed in ~~one of claims 1 to 8:claim 1.~~

18) The composition as claimed in ~~one of claims 15 to 17,claim 15,~~ wherein it moreover comprises primate T γ 9 δ 2 lymphocytes.

19) The composition as claimed in ~~one of claims 15 to 18,claim 15,~~ wherein it moreover comprises a proportion of interleukin suitable to bring about lymphocyte growth in the medium into which it is to be administered.

20) A process for the production of a composition having the characteristic of activating T γ 9 δ 2 lymphocytes, in which at least one compound as claimed in ~~one of claims 1 to 8:claim 1~~ is used.

21) A process for the production of a therapeutic composition intended for the preventive or curative treatment of a pathological condition which produces cells sensitive to T γ 9 δ 2 lymphocytes, in which process at least one compound as claimed in ~~one of claims 1 to 8:claim 1~~ is used.

22) A process for the production of a therapeutic composition intended to be administered to a primate for the preventive or curative treatment of a pathological condition which produces cells sensitive to T γ 9 δ 2 lymphocytes, in which process at least one compound as claimed in ~~one of claims 1 to 8:claim 1~~ is used.

23) A process for the production of a therapeutic composition intended to be administered to a primate for the preventive or curative treatment of a

pathological condition selected from among the group comprising cancers, infectious diseases, parasitic conditions, and pathological immunodeficiency syndromes, in which process at least one compound as claimed in ~~one of claims 1 to 8~~claim 1 is used.

24) The process according to claim ~~one of claims 20 to 23~~claim 20, in which at least one compound as claimed in one of claims 1 to 11 is brought into contact with a medium which contains $T_{\gamma 9\delta 2}$ lymphocytes, and is compatible with T lymphocyte growth, in a quantity suitable for activating these $T_{\gamma 9\delta 2}$ lymphocytes in this medium.

26) An extracorporeal $T_{\gamma 26\delta 9}$ lymphocyte activation process, in which the $T_{\gamma 9\delta 2}$ lymphocytes are brought into contact with at least one compound as claimed in ~~one of claims 1 to 8~~claim 1 in an extracorporeal medium which contains $T_{\gamma 9\delta 2}$ lymphocytes and is compatible with T lymphocyte growth.

27) The process as claimed in claim 26, in which at least one compound as claimed in ~~one of claims 1 to 8~~claim 1 is used at a concentration in the medium which brings about activation of polyclonal proliferation of $T_{\gamma 9\delta 2}$ lymphocytes.

28) The process as claimed in ~~one of claims 26 to 27~~claim 26, in which a proportion of interleukin suitable to bring about lymphocyte growth in the medium is introduced into the medium.